



## Stoke Therapeutics to Host Webinar and Conference Call to Present Interim Data from the Phase 1/2a Studies of STK-001 in Children and Adolescents with Dravet Syndrome

November 10, 2022

BEDFORD, Mass.--(BUSINESS WIRE)--Nov. 10, 2022-- [Stoke Therapeutics, Inc.](#) (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will hold a webinar and conference call for analysts and investors at 8:30 a.m. Eastern Time on Monday, November 14, 2022, to present data from a planned interim analysis of the Phase 1/2a studies of STK-001 in children and adolescents with Dravet syndrome.

To participate in the call, please dial (800) 715-9871, or (646) 307-1963 for international callers and provide conference call ID number 2168761. The webinar will be broadcast live on the Investors & News section of Stoke's website at <https://investor.stoketherapeutics.com/>, and can be accessed by following this [Link](#). An archive replay of the webinar will be available for at least 90 days following the event.

### About Stoke Therapeutics

Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines. Using Stoke's proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Stoke's first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. Dravet syndrome is one of many diseases caused by a haploinsufficiency, in which a loss of ~50% of normal protein levels leads to disease. Stoke is pursuing the development of STK-002 for the treatment of autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder. Stoke's initial focus is haploinsufficiencies and diseases of the central nervous system and the eye, although proof of concept has been demonstrated in other organs, tissues, and systems, supporting its belief in the broad potential for its proprietary approach. Stoke is headquartered in Bedford, Massachusetts with offices in Cambridge, Massachusetts. For more information, visit <https://www.stoketherapeutics.com/> or follow Stoke on Twitter at [@StokeTx](#).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20221110005166/en/): <https://www.businesswire.com/news/home/20221110005166/en/>

### Stoke Media & Investor Contacts:

Dawn Kalmar

Chief Communications Officer

[dkalmar@stoketherapeutics.com](mailto:dkalmar@stoketherapeutics.com)

781-303-8302

Eric Rojas

Vice President, Investor Relations

[IR@stoketherapeutics.com](mailto:IR@stoketherapeutics.com)

617-312-2754

Source: Stoke Therapeutics, Inc.